Ventana DLL3 RxDx assay

DEVICE2 trials

Sponsors

Boehringer Ingelheim

Conditions

Extra-pulmonary Neuroendocrine CarcinomaExtrapulmonary Neuroendocrine Cancer (epNEC)Neuroendocrine NeoplasmsSmall Cell Lung Carcinoma

Phase 2

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

RecruitingNCT05882058

Boehringer IngelheimExtra-pulmonary Neuroendocrine Carcinoma, Neuroendocrine Neoplasms, Small Cell Lung Carcinoma

Start: 2023-10-13End: 2028-06-08Target: 204Updated: 2026-07-23

Phase 3

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

RecruitingNCT07544654

Boehringer IngelheimExtrapulmonary Neuroendocrine Cancer (epNEC)

Start: 2026-07-10End: 2031-03-11Target: 390Updated: 2026-09-15

Related Papers

Analysis of delta-like ligand 3 (DLL3) expression levels and characteristics of patients (pts) with advanced extrapulmonary neuroendocrine carcinomas (epNECs) from an ongoing phase I trial.

Journal of Clinical Oncology2026-05-27

Abstract CT222: Obrixtamig (BI 764532) in patients with relapsed/refractory delta-like ligand 3 (DLL3) high-expressing extrapulmonary neuroendocrine carcinoma (epNEC): trial in progress of the dose expansion part of the Phase II DAREON-5 trial

Cancer Research2026-04-17

Abstract LB-A001: Obrixtamig (BI 764532) in patients with relapsed/refractory delta-like ligand 3 (DLL3) high-expressing extrapulmonary neuroendocrine carcinoma (epNEC): trial in progress of the dose expansion part of the Phase II DAREON-5 trial

Cancer Immunology Research2026-03-05

Obrixtamig (BI 764532) in patients (pts) with relapsed/refractory delta-like ligand 3 (DLL3)-high expressing extrapulmonary neuroendocrine carcinoma (epNEC): Dose expansion part of the phase II DAREON-5 trial.

Journal of Clinical Oncology2026-01-10

Abstract CT279: DareonTM-5: An open-label phase 2 trial of BI 764532, a DLL3-targeting T-cell engager, in patients (pts) with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas

Cancer Research2024-04-052 citations

Abstract LB_A16: DareonTM-5: An open-label Phase II trial of BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas

Molecular Cancer Therapeutics2023-12-011 citations